Recruiting
A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants - IM042-003
Actualizada: 10 mayo, 2022 | ClinicalTrials.gov
Imprimir Resumen
Detalles del estudio
Fase
Géneros
Rango de edad
Ubicación (es)
Recruiting
Opciones de tratamiento
Inclusion Criteria: - Healthy participants as determined by no clinically significant deviation from normal in medical history, physical examination, vital signs, ECGs, and clinical laboratory determinations - Body Mass Index (BMI) of 18.0 to 30.0 kg/m2, inclusive. BMI = weight (kg)/[height (m)]2 - Body weight ≥40.0 kg Exclusion Criteria: - History of clinically significant infection within 4 weeks of dosing on Day 1 - Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population - History of clinically significant allergic reaction to any drug, biologic, food or vaccine Other protocol-defined inclusion/exclusion criteria apply
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
